Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Concurrent Chemoradiation for Recurrent Cervical Cancer
NCT04974827Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Hunan Cancer Hospital. Primary endpoint: Complete Remission Rate. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04974827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974827.